Impact of Intensive Care Unit bed shortage on the short-term outcomes of major liver surgery during the pandemic: better safe than sorry?

BACKGROUND: Preoperative criteria to establish the need for intensive care unit (ICU) admission after major liver surgery have not been yet precisely defined and are often left to the anesthesiologist's judgment. The ICU bed shortage during the COVID-19 pandemic has challenged healthcare systems around the world. We sought to determine its impact on early outcomes of elective major liver surgery. METHODS: We performed a retrospective analysis of consecutive patients undergoing major oncological liver surgery from a single institution. Two time periods were compared considering a complete ban on ICU beds during the pandemic (index period, from November 2020 to May 2021), and the smoothly running ICU facility before the pandemic (control period, from November 2018 to October 2020). The main outcomes were 30-day morbidity and mortality, length-of-stay, and 30-day readmission rates. RESULTS: Overall, 57 consecutive patients were identified, of whom 18 (32%) in the index period, and 39 (68%) in the control period, with 24 (62%) patients in the latter group admitted to ICU. No significant differences were found in terms of ASA Score, P-POSSUM morbidity and mortality, operative times, and red blood cells transfusions between groups. The morbidity rate, as classified by the Clavien-Dindo system, was also similar. A slightly longer length-of-stay has been observed in the index period (mean difference of 1.12 [95% CI, -9.19;11.42] days; P=0.829) after controlling for age, gender, ASA Score, and P-POSSUM. The 30-day readmission rate was comparable between the index and control periods (5.0% vs. 4.8%, respectively). CONCLUSIONS: The ICU bed shortage in response to the COVID-19 emergency did not negatively impact on the early postoperative outcomes of major liver surgery.

Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: Results From an Italian Cohort of 133 Hypertensives.

BACKGROUND: The effect of chronic use of renin-angiotensin-aldosterone system (RAAS) inhibitors on the severity of COVID-19 infection is still unclear in patients with hypertension. We aimed to investigate the association between chronic use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and COVID-19-related outcomes in hypertensive patients. METHODS: A single-center study was conducted on 133 consecutive hypertensive subjects presenting to the emergency department with acute respiratory symptoms and/or fever who were diagnosed with COVID-19 infection between 9 and 31 March 2020. RESULTS: All patients were grouped according to their chronic antihypertensive medications (ACEIs, N = 40; ARBs, N = 42; not on RAAS inhibitors, N = 51). There was no statistical difference between ACEIs and ARBs groups in terms of hospital admission rate, oxygen therapy, and need for noninvasive ventilation. Patients chronically treated with RAAS inhibitors showed a significantly lower rate of admission to semi-intensive/intensive care units, when compared with the non-RAAS population (odds ratio (OR) 0.25, confidence interval (CI) 95% 0.09-0.66, P = 0.006). Similarly, the risk of mortality was lower in the former group, although not reaching statistical significance (OR 0.56, CI 95% 0.17-1.83, P = 0.341). CONCLUSIONS: Our data suggest that chronic use of RAAS inhibitors does not negatively affect clinical course of COVID-19 in hypertensive patients. Further studies are needed to confirm this finding and determine whether RAAS inhibitors may have a protective effect on COVID-19-related morbidity and mortality.